This inventor holds 7 USPTO granted patents and 6 published patent applications and 1 EPO patent. Top assignee: Schering Corporation. Active years: 2002-2012.
Location History:
- Edison, NJ (US) (2002 - 2008)
- Sandy, UT (US) (2012)
Company Filing History:
Years Active: 2002-2012
Title: The Innovative Contributions of Mark A. Laughlin
Introduction
Mark A. Laughlin is a notable inventor based in Edison, NJ, with a significant portfolio of seven patents. His work primarily focuses on the development of pharmaceutical compounds, particularly in the area of CCR5 antagonists.
Latest Patents
Among his latest patents is a groundbreaking invention involving Piperazine derivatives useful as CCR5 antagonists. This patent outlines the use of CCR5 antagonists of a specific formula or a pharmaceutically acceptable salt thereof, showcasing his innovative approach to addressing medical challenges.
Career Highlights
Mark A. Laughlin has made substantial contributions to the field of pharmaceuticals during his career at Schering Corporation. His expertise in medicinal chemistry and drug development has positioned him as a key player in the industry.
Collaborations
Throughout his career, Laughlin has collaborated with esteemed colleagues, including Bahige M. Baroudy and John W. Clader. These partnerships have fostered a collaborative environment that enhances the innovation process.
Conclusion
Mark A. Laughlin's contributions to the field of pharmaceuticals through his patents and collaborations highlight his role as a significant inventor. His work continues to impact the development of new therapeutic agents.